ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 8| August 2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753|| ISI Value: 1.188

DIABETIC NEUROPATHY: PATHOPHYSIOLOGY AND RECENT THERAPEUTIC APPROACHES

Soni Kumari
Assistant Professor, Teachers' Training College, Bhagalpur, Bihar, India

1. ABSTRACT

Diabetic neuropathy is a common and debilitating complication of diabetes mellitus, resulting from complex metabolic, vascular, oxidative and inflammatory processes that progressively impair peripheral nerve function. It may present with sensory loss, neuropathic pain, weakness, autonomic dysfunction and, in advanced cases, diabetic foot complications. Despite improvements in diabetes management, effective disease-modifying therapies for established neuropathy remain limited, and current clinical management largely focuses on risk-factor modification and symptomatic control. This review provides an overview of the pathophysiology of diabetic neuropathy and recent therapeutic approaches, with emphasis on the mechanisms underlying nerve injury and emerging strategies aimed at improving treatment outcomes. Major pathogenic mechanisms include chronic hyperglycaemia, oxidative stress, mitochondrial dysfunction, advanced glycation, metabolic disturbances, microvascular impairment and neuroinflammation. Recent therapeutic developments include improved pharmacological management of neuropathic pain, neuromodulation, regenerative approaches, molecularly targeted therapies and emerging strategies directed towards neuroprotection and nerve repair.

The evolving evidence suggests a gradual shift from predominantly symptomatic treatment towards mechanism-based and potentially disease-modifying approaches. However, many emerging therapies remain under investigation, and their clinical effectiveness requires confirmation through well-designed clinical trials. A better understanding of disease mechanisms together with advances in early diagnosis, targeted therapy and multidisciplinary management may improve outcomes and reduce the long-term burden of diabetic neuropathy.

KEYWORDS: *Diabetic Neuropathy, Diabetic Peripheral Neuropathy, Pathophysiology; Neuropathic Pain; Oxidative Stress, Neuroinflammation, Emerging Therapies.*

2. INTRODUCTION

Diabetes mellitus is a major metabolic disorder associated with a wide range of chronic microvascular and macrovascular complications. Among its neurological complications, diabetic neuropathy represents a clinically important and heterogeneous group of disorders resulting from damage to the peripheral and autonomic nervous systems. Diabetic peripheral neuropathy, particularly distal symmetric polyneuropathy, is the most common form and may develop insidiously, with some individuals remaining asymptomatic despite significant nerve dysfunction. Early recognition is therefore important because progressive sensory impairment can increase the risk of unnoticed trauma, diabetic foot ulceration and subsequent disability. The clinical burden of diabetic neuropathy extends beyond sensory symptoms. Depending on the type and distribution of nerve involvement, patients may experience burning pain, tingling, numbness, altered temperature or vibration sensation, weakness, impaired balance and loss of protective sensation. Autonomic involvement may additionally affect cardiovascular, gastrointestinal, genitourinary and sudomotor functions. Painful neuropathy can substantially interfere with sleep, mobility, psychological well-being and overall quality of life. The development of diabetic neuropathy is not attributable to a single pathological mechanism. Persistent metabolic abnormalities associated with diabetes initiate a complex network of biochemical and cellular changes within peripheral nerves and their supporting vascular and glial structures. Hyperglycaemia, abnormal lipid metabolism and impaired insulin signalling contribute to oxidative stress, mitochondrial dysfunction, advanced glycation, microvascular injury and inflammatory responses. These processes interact with one another and ultimately promote axonal dysfunction, neuronal injury and impaired nerve repair.

Despite substantial progress in understanding these mechanisms, treatment remains challenging. Current clinical management emphasises optimisation of glycaemic control and other modifiable risk factors, together with appropriate management of neuropathic pain and prevention of secondary complications. However, current therapies are largely directed toward preventing progression or controlling symptoms rather than reliably reversing established neuronal damage. The 2026 American Diabetes Association Standards of Care recommend optimisation of glucose, weight, blood pressure and lipid management, while gabapentinoids, serotonin–norepinephrine reuptake inhibitors, tricyclic antidepressants and sodium-channel blockers remain important pharmacological options for painful diabetic neuropathy. These therapeutic limitations have intensified interest in recent and emerging approaches that target the underlying mechanisms of nerve injury. Advances in understanding oxidative stress, mitochondrial dysfunction, neuroinflammation, metabolic signalling and impaired nerve regeneration have opened possibilities for more mechanism-based interventions. Consequently, contemporary research is increasingly exploring strategies that may move diabetic

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 8| August 2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753|| ISI Value: 1.188

neuropathy management beyond conventional symptomatic treatment toward neuroprotection, nerve repair and disease modification. Against this background, the present review focuses on the classification, epidemiology and risk factors, underlying pathophysiology, clinical manifestations and diagnosis, current therapeutic approaches, and recent and emerging treatment strategies for diabetic neuropathy. A clearer understanding of the mechanisms driving nerve injury, together with evaluation of evolving therapeutic options, is essential for improving early recognition, clinical management and future development of more effective interventions.

3. CLASSIFICATION, EPIDEMIOLOGY AND RISK FACTORS

Diabetic neuropathy represents a heterogeneous group of neurological disorders associated with diabetes mellitus, with different patterns of nerve involvement and clinical presentation. Among these, distal symmetric polyneuropathy (DSPN) is the most common form and predominantly affects the longest nerves, producing a characteristic length-dependent pattern that usually begins in the feet and may progressively involve the hands. Other clinically important forms include diabetic autonomic neuropathy, which may affect cardiovascular, gastrointestinal, genitourinary and sudomotor functions, as well as focal and multifocal neuropathies that may present with more localized or asymmetric neurological deficits. Recognition of this clinical heterogeneity is important because neuropathy in a person with diabetes is a diagnosis of exclusion and other potentially treatable causes of nerve dysfunction must also be considered. Diabetic peripheral neuropathy represents a substantial global health burden. Current evidence indicates that peripheral neuropathy may affect up to approximately 50% of people with diabetes, although reported prevalence varies according to population characteristics, diagnostic criteria, disease duration and methods of assessment. Importantly, a considerable proportion of cases may remain asymptomatic, allowing progressive loss of protective sensation to occur without the patient's awareness. This increases susceptibility to unnoticed trauma, diabetic foot ulceration, infection and, in severe cases, lower-limb amputation.

The epidemiology of painful diabetic peripheral neuropathy is particularly relevant because neuropathic pain can substantially impair sleep, mobility and quality of life. A recent systematic review and meta-analysis estimated the global prevalence of painful diabetic peripheral neuropathy at approximately 46.7% among individuals with diabetic peripheral neuropathy, although considerable variation exists between studies and diagnostic approaches. The development and progression of diabetic neuropathy are influenced by multiple metabolic and clinical factors. Duration of diabetes and chronic hyperglycaemia remain important determinants of neuropathic risk, reflecting the cumulative effects of metabolic injury on peripheral nerves. However, contemporary evidence indicates that hyperglycaemia alone does not explain the entire disease process. Obesity, dyslipidaemia, hypertension, renal disease and other metabolic abnormalities also contribute to neuropathy risk, supporting a broader concept of metabolic dysfunction in its pathogenesis. Age and duration of diabetes are important clinical risk factors, while sex-related differences have also been reported in studies of painful diabetic neuropathy. The presence of other diabetic complications, particularly diabetic nephropathy and retinopathy, is associated with increased neuropathic risk and may reflect a broader burden of microvascular and metabolic disease. Cardiovascular disease and hypertension have likewise been associated with increased risk. Recent meta-analytic evidence has additionally identified higher body mass index and longer diabetes duration among important factors associated with painful diabetic neuropathy.

Overall, the epidemiology of diabetic neuropathy demonstrates that its development is multifactorial and cannot be attributed exclusively to poor glycaemic control. The interaction of hyperglycaemia, metabolic abnormalities, vascular factors, duration of diabetes and coexisting complications contributes to individual susceptibility. This multifactorial nature provides an important foundation for understanding the complex pathophysiology of diabetic neuropathy and the need for therapeutic strategies that extend beyond glycaemic control alone.

4. PATHOPHYSIOLOGY OF DIABETIC NEUROPATHY

The pathophysiology of diabetic neuropathy is complex and multifactorial, involving the interaction of metabolic, oxidative, mitochondrial, vascular, inflammatory and neurotrophic mechanisms. Although chronic hyperglycaemia remains a major initiating factor, current evidence indicates that diabetic neuropathy cannot be explained by hyperglycaemia alone. Dyslipidaemia, insulin resistance, microvascular dysfunction and altered cellular signalling contribute to a progressive environment of metabolic and oxidative stress that ultimately damages neurons, axons, Schwann cells and the supporting microvasculature.

Hyperglycaemia and Metabolic Stress

Persistent elevation of blood glucose increases the metabolic burden on peripheral nerves. Excess intracellular glucose is diverted into several biochemical pathways, particularly the polyol, advanced glycation end-product (AGE), protein kinase C (PKC) and hexosamine pathways. These pathways disturb normal cellular metabolism, increase oxidative stress and interfere with neuronal and Schwann-cell function. The resulting metabolic imbalance contributes to axonal injury and impaired nerve function. The polyol pathway is activated when excess glucose is converted to sorbitol by aldose reductase and subsequently to fructose. Increased activity of this pathway alters cellular redox balance and consumes NADPH, thereby reducing the availability of reducing equivalents required for antioxidant defence. Accumulation of metabolic intermediates and associated oxidative stress can contribute to Schwann-cell dysfunction and axonal damage.

In parallel, non-enzymatic glycation promotes the formation of advanced glycation end products (AGEs). These products can modify proteins and cellular structures and interact with their receptor, RAGE, initiating downstream inflammatory

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 8| August 2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753|| ISI Value: 1.188

and oxidative signalling. AGE accumulation can therefore contribute to vascular dysfunction, altered neuronal proteins and progressive nerve injury.

Oxidative Stress

Oxidative stress is one of the central mechanisms linking metabolic abnormalities to neural injury in diabetic neuropathy. Persistent hyperglycaemia and dyslipidaemia increase the generation of reactive oxygen species (ROS), while simultaneously impairing endogenous antioxidant defence mechanisms. Excess ROS can damage lipids, proteins and DNA and interfere with normal neuronal signalling and cellular survival. Oxidative stress does not operate independently. It interacts with the polyol pathway, AGE formation, PKC signalling and inflammatory pathways, creating a self-reinforcing cycle of cellular injury. This interaction is important because it explains why targeting a single metabolic abnormality may not be sufficient to reverse established neuropathy. Recent research consequently considers oxidative stress an important therapeutic target, although clinical evidence for consistently disease-modifying antioxidant treatment remains limited.

Mitochondrial Dysfunction and Energy Failure

Peripheral neurons have high energy requirements and depend heavily on mitochondrial function for ATP production, axonal transport and maintenance of cellular integrity. Diabetes-associated metabolic stress can impair mitochondrial oxidative phosphorylation, alter mitochondrial dynamics and increase mitochondrial ROS production. Damaged mitochondria consequently become both a source and a target of oxidative stress. Mitochondrial dysfunction can result in reduced ATP availability, impaired axonal transport and activation of apoptotic pathways. Disturbances in mitochondrial trafficking and quality control may particularly affect long peripheral axons, helping explain the characteristic length-dependent pattern of diabetic peripheral neuropathy. Dysfunction of mitochondria within Schwann cells may further compromise myelin maintenance and neuronal support.

Microvascular Dysfunction and Neural Ischaemia

Peripheral nerves depend on an extensive microvascular network to maintain adequate oxygen and nutrient delivery. Diabetes can impair this neurovascular environment through endothelial dysfunction, abnormal vascular signalling and reduced nerve blood flow. Microvascular abnormalities may therefore contribute to neural hypoxia and metabolic stress. The interaction between metabolic injury and microvascular dysfunction is particularly important because reduced perfusion can further increase oxidative stress and compromise the ability of peripheral nerves to maintain normal function and repair damaged axons. Thus, diabetic neuropathy is increasingly understood as a disorder involving the neurovascular unit, rather than an isolated neuronal abnormality.

Neuroinflammation

Chronic metabolic and oxidative stress activates inflammatory pathways within peripheral nerves. Neurons, Schwann cells, macrophages and other immune-related cellular components can participate in this inflammatory response. Increased inflammatory signalling may alter neuronal excitability, promote pain sensitisation and contribute to progressive axonal degeneration. Recent research has highlighted pathways involving NF-κB, NLRP3 inflammasome signalling, Toll-like receptors and other inflammatory mediators. Importantly, oxidative stress and inflammation reinforce each other: excessive ROS can activate inflammatory signalling, while inflammatory processes can further increase oxidative damage. This reciprocal relationship may contribute to the persistence of neuropathic pain and nerve degeneration.

Impaired Insulin Signalling and Neurotrophic Support

Insulin has functions within peripheral nerves that extend beyond glucose regulation. Impaired insulin signalling associated with diabetes can interfere with neuronal survival, axonal maintenance and repair mechanisms. Reduced activity of intracellular pathways involved in neuronal growth and survival may consequently limit the capacity of damaged nerves to regenerate. Altered neurotrophic signalling may further compromise communication between neurons and supporting Schwann cells. This combination of impaired metabolic signalling and reduced repair capacity contributes to the persistence and progression of neuropathic injury.

Interaction of Pathogenic Mechanisms

The major mechanisms involved in diabetic neuropathy should not be considered as independent pathways. Hyperglycaemia and dyslipidaemia initiate metabolic stress; metabolic disturbances increase ROS generation and mitochondrial dysfunction; oxidative stress and AGE-related signalling promote inflammation and vascular injury; and these processes collectively impair neuronal survival, axonal transport, Schwann-cell function and nerve repair. This interconnected pathophysiology is clinically important because it explains the difficulty in developing a single disease-modifying treatment. Although several molecular targets have demonstrated promising results in experimental models, translation into consistent clinical benefit has remained challenging. Current research is therefore increasingly focused on multitarget and mechanism-based approaches, including modulation of oxidative stress, mitochondrial function, inflammatory signalling, metabolic pathways and neuroregenerative processes.

Overall, diabetic neuropathy can be viewed as the consequence of a progressive interaction between metabolic overload, oxidative and mitochondrial injury, microvascular dysfunction, inflammation and impaired neural repair. Understanding this interconnected network provides the biological foundation for developing newer therapeutic strategies aimed not only at controlling neuropathic symptoms but also at preventing or reversing the underlying nerve damage.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 8| August 2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753|| ISI Value: 1.188

5. CLINICAL MANIFESTATIONS AND DIAGNOSIS

The clinical presentation of diabetic neuropathy varies according to the type of nerve involved, the severity of nerve damage and the stage of disease. Distal symmetric polyneuropathy (DSPN) is the most common clinical form and typically follows a length-dependent pattern, beginning in the toes and feet before progressing proximally and, in more advanced disease, involving the hands. However, a substantial proportion of patients may have neuropathy without obvious symptoms, making systematic clinical assessment particularly important. The American Diabetes Association (ADA) recommends assessment for diabetic peripheral neuropathy at the time of diagnosis of type 2 diabetes, five years after diagnosis of type 1 diabetes, and at least annually thereafter. The symptoms of diabetic peripheral neuropathy depend largely on whether small or large sensory fibres are predominantly affected. Small-fibre involvement commonly produces burning, tingling, prickling, shooting or electric-like pain and abnormal sensitivity. Patients may also experience pain from normally non-painful stimuli. Large-fibre involvement is more commonly associated with numbness, impaired vibration and proprioception, reduced reflexes, balance disturbances and loss of protective sensation. Progressive loss of protective sensation is clinically important because patients may fail to recognise minor injuries, burns or pressure-related trauma to the feet.

Motor involvement may occur in more advanced or atypical neuropathic presentations and can produce muscle weakness, impaired coordination and functional difficulties. Loss of sensation combined with motor abnormalities may contribute to altered gait and increased risk of falls. In the lower limbs, chronic sensory loss can also contribute indirectly to foot deformity, pressure redistribution and ulcer formation. Painful diabetic peripheral neuropathy represents an especially important manifestation because persistent neuropathic pain can substantially affect sleep, mobility, psychological well-being and quality of life. The intensity of pain does not necessarily correspond directly to the degree of sensory loss. Some individuals may experience severe neuropathic pain despite relatively limited findings on routine examination, whereas others may have considerable sensory loss with little or no pain. Diabetic neuropathy may also involve the autonomic nervous system. Cardiovascular autonomic neuropathy can manifest as resting tachycardia, exercise intolerance and orthostatic hypotension. Gastrointestinal involvement may produce gastroparesis, constipation or diarrhoea, while genitourinary involvement can result in bladder dysfunction or erectile dysfunction. Abnormal sweating, including excessive or reduced sweating, represents another manifestation of autonomic involvement. Recognition of these symptoms is important because autonomic neuropathy may significantly affect quality of life and, in cardiovascular involvement, may contribute to clinically important complications.

DIAGNOSIS

Diabetic neuropathy is fundamentally a clinical diagnosis and a diagnosis of exclusion. The presence of diabetes does not automatically mean that every neuropathy is diabetic in origin. Other potentially treatable causes, including vitamin B12 deficiency, thyroid disease, renal disease, alcohol exposure, neurotoxic medications, inflammatory neuropathies and inherited neurological disorders, should be considered when clinical findings are atypical or unexplained. The initial evaluation involves a detailed history and neurological examination. The clinician should assess the distribution and character of symptoms, duration of diabetes, glycaemic history, presence of neuropathic pain and associated complications. Examination should include assessment of sensory function, reflexes, muscle strength, gait and the condition of the feet. Simple bedside tests are particularly valuable. Pinprick or temperature testing can provide information regarding small-fibre function, whereas vibration testing with a 128-Hz tuning fork, assessment of ankle reflexes and evaluation of proprioception provide information regarding large-fibre function. The 10-g monofilament test is widely used to identify loss of protective sensation and patients at increased risk of diabetic foot ulceration. Current ADA guidance recommends that monofilament assessment should be performed together with at least one additional neurological assessment rather than being used as the sole diagnostic test.

Electrophysiological investigations, including nerve conduction studies and electromyography, are not routinely necessary in typical diabetic peripheral neuropathy. They become more useful when the presentation is atypical, rapidly progressive, markedly asymmetric, predominantly motor, non-length-dependent or when an alternative neurological diagnosis is suspected. Additional investigations may be selected according to the clinical presentation and may include laboratory testing for potentially reversible causes of neuropathy. Early identification is clinically important because neuropathy may be present before patients recognise significant symptoms. Regular neurological and foot assessment allows clinicians to identify loss of protective sensation and introduce preventive measures before minor injuries progress to ulceration or other serious complications. Thus, the clinical assessment of diabetic neuropathy should combine symptom recognition, neurological examination, objective sensory testing and evaluation for alternative causes, providing the foundation for appropriate therapeutic management.

6. CURRENT THERAPEUTIC APPROACHES

The management of diabetic neuropathy is currently directed toward two major goals: slowing or preventing further nerve damage and controlling the symptoms associated with neuropathy, particularly neuropathic pain. At present, no treatment has consistently demonstrated the ability to reverse established diabetic nerve damage. Therefore, effective management requires a combination of metabolic risk-factor control, symptomatic pharmacotherapy, prevention of complications and appropriate management of associated comorbidities.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 8| August 2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753|| ISI Value: 1.188

Glycaemic and Metabolic Management

Optimisation of glycaemic control remains a fundamental component of diabetic neuropathy management. Sustained improvement in glucose control, particularly when implemented early, can reduce the risk of developing neuropathy and may slow its progression. The evidence is strongest in type 1 diabetes, whereas in type 2 diabetes the effect on established neuropathy is more modest. Importantly, improved glycaemic control should not be considered a treatment capable of reversing established neuronal loss. Management should therefore extend beyond blood glucose alone. Current evidence supports optimisation of body weight, blood pressure and lipid levels, as these metabolic and cardiovascular risk factors are associated with the development and progression of diabetic neuropathy. A broader cardiometabolic approach is particularly relevant in type 2 diabetes, where insulin resistance, obesity and dyslipidaemia may contribute to peripheral nerve injury.

Pharmacological Management of Neuropathic Pain

Painful diabetic peripheral neuropathy is primarily managed with medications that modulate abnormal neuronal signalling. According to the current ADA Standards of Care, gabapentinoids, serotonin–norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs) and sodium-channel blockers are recommended initial pharmacological options. Selection should be individualised according to pain severity, comorbidities, adverse-effect profiles, drug interactions, age and patient preferences.

Gabapentinoids, particularly pregabalin and gabapentin, reduce neuronal excitability through interaction with the α2-δ subunit of voltage-gated calcium channels. Pregabalin has substantial evidence supporting its efficacy in painful diabetic peripheral neuropathy, while gabapentin is also an established therapeutic option. Mirogabalin, another α2-δ ligand, has demonstrated a more modest effect and may be considered in appropriate clinical settings. Sedation, dizziness and other adverse effects should be considered, particularly in older patients.

SNRIs, especially duloxetine, represent another important treatment group. Duloxetine has strong clinical evidence for reducing neuropathic pain and may be particularly useful when painful neuropathy coexists with mood-related symptoms. Venlafaxine also has supportive evidence, although the evidence base is less extensive than that for duloxetine.

Tricyclic antidepressants, particularly amitriptyline, can provide significant analgesic benefit. However, their anticholinergic and cardiovascular adverse effects may limit their use, especially among older adults or patients with relevant comorbidities. Consequently, although effective, TCAs require careful patient selection and monitoring.

Sodium-channel blockers constitute another therapeutic category. Agents such as carbamazepine, oxcarbazepine, lacosamide and related drugs have been investigated for painful diabetic neuropathy, although their clinical role varies according to the available evidence and individual patient circumstances.

Topical Therapies

Topical treatment can be useful when pain is relatively localised or when systemic medications are poorly tolerated. Capsaicin, particularly the high-concentration 8% patch, has demonstrated efficacy in painful diabetic peripheral neuropathy and provides a non-systemic treatment option. Lower-concentration capsaicin preparations may also be used in selected patients. Topical lidocaine preparations may provide local analgesic benefit in some patients, although evidence is more limited and their usefulness is generally greater for localised rather than widespread neuropathic pain.

Combination Therapy

Not all patients obtain adequate pain relief from a single medication. Current evidence suggests that combination pharmacotherapy may provide additional benefit in individuals who have an inadequate response to monotherapy. Combining agents from different therapeutic classes may allow complementary mechanisms of analgesia while potentially permitting lower doses of individual drugs. Treatment should nevertheless be individualised because combining medications can also increase adverse effects and drug burden.

Non-pharmacological and Preventive Management

Pharmacological treatment should be accompanied by preventive measures aimed at reducing complications of sensory loss. Regular foot examination, patient education, appropriate footwear and early management of minor foot injuries are essential, particularly in individuals with loss of protective sensation. Prevention is important because neuropathy may be asymptomatic, yet progressive sensory loss can increase the risk of unnoticed trauma, diabetic foot ulceration and subsequent disability. Lifestyle and risk-factor modification also form an important part of comprehensive management. Physical activity, appropriate weight management, optimisation of blood pressure and lipid levels, and sustained diabetes management can contribute to reducing the overall risk of neuropathy progression. These interventions should be integrated with pharmacological treatment rather than considered substitutes for evidence-based management of established neuropathic pain.

Management of Autonomic Neuropathy

Treatment must also be adapted to the specific manifestations of diabetic autonomic neuropathy. Cardiovascular, gastrointestinal, genitourinary and sudomotor manifestations require symptom-specific assessment and management. For example, orthostatic hypotension may require non-pharmacological measures such as adequate fluid and salt intake, avoidance of aggravating medications and use of compression garments, with pharmacological treatment considered when necessary. The objective is generally to reduce symptoms and improve functional status rather than simply normalising physiological measurements.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 8| August 2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753|| ISI Value: 1.188

Limitations of Current Treatment

Despite the availability of several effective symptomatic treatments, an important limitation remains: current standard therapies primarily control symptoms and do not reliably restore damaged peripheral nerves. Even optimal glycaemic and metabolic management cannot consistently reverse established neuronal loss. This therapeutic gap has become a major driving force behind research into mechanism-based and disease-modifying therapies.

Thus, current management of diabetic neuropathy is best understood as a multidimensional strategy combining metabolic control, evidence-based pain management, complication prevention and treatment of autonomic manifestations. While these approaches can substantially improve symptoms and quality of life, their limitations provide the rationale for the development of newer therapies aimed directly at the underlying mechanisms of nerve injury and regeneration.

7. RECENT AND EMERGING THERAPEUTIC APPROACHES

The limitations of conventional treatment have encouraged the development of therapeutic strategies aimed not only at controlling neuropathic pain but also at addressing the underlying mechanisms of nerve injury. Recent research has increasingly focused on neuromodulation, regenerative therapies, metabolic and molecular targets, novel drug-delivery systems and approaches designed to promote nerve repair. Although several of these strategies have produced encouraging results, many remain under clinical investigation and require further evidence before routine use. One of the most important recent developments is high-frequency spinal cord stimulation (SCS). Conventional SCS has been used for selected patients with refractory painful diabetic neuropathy, but newer stimulation paradigms have demonstrated clinically meaningful improvements in pain and quality of life. In particular, 10-kHz SCS has shown sustained benefit in patients with painful diabetic neuropathy that is inadequately controlled with conventional medical management. Its potential advantage is that it can provide substantial analgesia without relying primarily on the traditional paresthesia-based mechanism of spinal stimulation. Recent clinical evidence has strengthened the position of SCS as an option for carefully selected patients with refractory painful diabetic neuropathy. (pubmed.ncbi.nlm.nih.gov)

Another emerging neuromodulation strategy is dorsal root ganglion stimulation (DRG-S). By targeting neural structures involved in sensory signalling more selectively, DRG stimulation may offer an alternative for patients with persistent focal or difficult-to-treat neuropathic pain. Although the evidence base remains smaller than that for conventional and high-frequency SCS, neuromodulation represents an important shift toward approaches that directly modify abnormal pain signalling rather than relying exclusively on systemic analgesic medication. Regenerative medicine and cell-based therapies represent another promising area. Diabetes can impair endogenous mechanisms of nerve repair through oxidative stress, inflammation, vascular dysfunction and altered neurotrophic signalling. Mesenchymal stem cells and their secreted factors have therefore attracted interest because of their potential anti-inflammatory, angiogenic and neurotrophic effects. Experimental studies suggest that cell-derived growth factors and extracellular vesicles may support neuronal survival and repair. However, clinical translation remains challenging, and questions concerning cell source, delivery, dosing, durability, safety and reproducibility need to be resolved before these approaches can be considered established treatments.

Neurotrophic and growth-factor-based strategies have also been investigated because impaired trophic support contributes to axonal degeneration and limited regeneration. Agents capable of enhancing neurotrophic signalling could theoretically promote neuronal survival and axonal repair. Despite encouraging preclinical findings, clinical trials of individual growth factors have produced inconsistent outcomes, partly because effective delivery to peripheral nerves and appropriate patient selection remain difficult. Current research is consequently exploring more targeted methods of delivering regenerative signals to damaged neural tissue. The growing understanding of mitochondrial dysfunction and oxidative stress has generated interest in therapies directed toward mitochondrial protection and restoration of cellular redox balance. Experimental approaches include mitochondrial antioxidants, agents influencing mitochondrial biogenesis and strategies designed to improve mitochondrial quality control. These approaches are mechanistically attractive because mitochondrial dysfunction occupies a central position in the interaction between metabolic stress and neuronal injury. Nevertheless, convincing evidence of clinically meaningful disease modification remains limited, and antioxidant strategies have not yet translated consistently into standard clinical practice.

Another emerging direction involves targeting neuroinflammation. Chronic activation of inflammatory pathways can contribute to neuronal sensitisation and axonal degeneration. Research has therefore examined inflammatory mediators, immune-cell activation and intracellular pathways such as NF-κB and NLRP3 inflammasome signalling as potential therapeutic targets. Modulating these pathways may theoretically reduce both pain and progressive nerve injury. However, because inflammation also participates in normal tissue repair and immune regulation, therapeutic strategies must achieve sufficient selectivity to avoid undesirable systemic effects. Increasing attention has also been directed toward metabolic and lipid-related mechanisms. Dyslipidaemia and abnormal fatty-acid metabolism appear to contribute to peripheral nerve injury independently of hyperglycaemia. This has encouraged investigation of therapies targeting lipid metabolism, insulin signalling and related metabolic pathways. Such approaches are particularly relevant to type 2 diabetes, where obesity, insulin resistance and dyslipidaemia frequently coexist and may contribute collectively to neuropathic risk.

Novel drug-delivery approaches may further improve the treatment of painful diabetic neuropathy. Conventional systemic medications can be limited by sedation, dizziness, gastrointestinal effects and other dose-related adverse events. Targeted or local

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 8| August 2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753|| ISI Value: 1.188

delivery systems are being explored to increase therapeutic exposure at relevant sites while reducing systemic toxicity. Advances in nanotechnology and controlled-release formulations may eventually allow more precise delivery of analgesic or neuroprotective agents, although most such technologies remain at experimental or early translational stages. A particularly important development is the increasing interest in disease-modifying therapies. Traditional pharmacological treatment is largely focused on reducing pain without necessarily reversing the underlying neuronal pathology. Current research is attempting to identify interventions that can interrupt pathological pathways early enough to preserve axons, improve Schwann-cell function, restore microvascular support or stimulate regeneration. Such approaches include combinations of metabolic, antioxidant, anti-inflammatory and neurotrophic strategies rather than reliance on a single molecular target.

Recent evidence also supports continued investigation of non-invasive and device-based interventions. Physical activity and structured exercise may influence metabolic health, vascular function, mitochondrial activity and neural function, while newer forms of peripheral and central neuromodulation are being investigated for patients who do not obtain adequate relief from medication. These approaches may be particularly valuable when integrated into multidisciplinary treatment rather than used as isolated interventions. An important consideration in the development of new therapies is the distinction between symptomatic efficacy and true disease modification. A therapy that reduces pain may improve quality of life without reversing the underlying nerve degeneration. Conversely, a therapy capable of improving nerve structure or function may require longer follow-up to demonstrate clinical benefit. Future trials therefore need to incorporate meaningful neurological, functional and patient-reported outcomes rather than relying exclusively on short-term pain scores.

Overall, recent therapeutic research demonstrates a gradual transition from conventional symptom control toward mechanism-based, regenerative and neuromodulatory approaches. High-frequency spinal cord stimulation currently represents one of the more clinically advanced emerging interventions for refractory painful diabetic neuropathy, whereas cell-based therapies, neurotrophic strategies, mitochondrial targets, anti-inflammatory approaches and advanced drug-delivery systems remain promising areas of investigation. Continued translational research is essential to determine which of these approaches can ultimately provide durable nerve protection or repair and become part of routine clinical management.

8. CHALLENGES AND FUTURE PERSPECTIVES

Despite considerable advances in the understanding and management of diabetic neuropathy, effective treatment remains a major clinical challenge. The complexity of its pathophysiology, delayed diagnosis, heterogeneity of clinical presentation and limited availability of disease-modifying therapies continue to restrict therapeutic progress. Most currently available treatments are directed primarily toward controlling neuropathic pain and preventing complications rather than restoring damaged peripheral nerves. One of the major challenges is the multifactorial nature of disease progression. Hyperglycaemia, dyslipidaemia, oxidative stress, mitochondrial dysfunction, microvascular impairment and neuroinflammation interact through multiple biological pathways. Consequently, targeting a single mechanism may provide insufficient protection against progressive nerve injury. Future therapeutic development may therefore require multitarget approaches capable of simultaneously addressing metabolic, vascular, inflammatory and neuronal abnormalities. Early diagnosis and identification of individuals at high risk represent another important priority. Diabetic neuropathy may remain clinically silent during its early stages, while irreversible nerve damage can develop progressively. Greater use of sensitive neurological and functional assessments, together with emerging biomarkers and objective measures of small-fibre dysfunction, could facilitate earlier intervention. Earlier treatment may provide a greater opportunity to prevent progression than treatment initiated after substantial axonal loss has already occurred.

A major unmet need is the development of reliable disease-modifying therapies. Although numerous experimental interventions have demonstrated neuroprotective or regenerative effects, relatively few have produced consistent benefits in clinical studies. Future research should therefore distinguish clearly between treatments that merely reduce pain and those that genuinely improve nerve structure, function or regeneration. Clinical trials also face important methodological challenges. Diabetic neuropathy is heterogeneous, and differences in disease duration, diabetes type, metabolic control, neuropathy severity and pain phenotype can substantially influence treatment response. Future studies should use better-defined patient populations, sufficiently long follow-up periods and validated neurological and patient-reported outcome measures. Combining clinical outcomes with objective measures of nerve function may provide a more accurate assessment of therapeutic efficacy. Precision medicine may become increasingly important in the future. Patients with diabetic neuropathy may differ considerably in the dominant mechanisms contributing to their nerve injury. Identification of metabolic, inflammatory, vascular or genetic characteristics associated with specific neuropathic phenotypes could eventually allow treatment to be selected according to individual biological mechanisms rather than using the same therapeutic strategy for all patients.

The future therapeutic landscape is also likely to involve greater integration of neuromodulation, regenerative medicine, molecularly targeted therapy and advanced drug-delivery systems. High-frequency spinal cord stimulation has already demonstrated clinically meaningful benefits in selected patients with refractory painful diabetic neuropathy, while cell-based therapies, neurotrophic approaches, mitochondrial interventions and anti-inflammatory strategies remain under investigation. Translating these promising approaches into routine clinical practice will require robust evidence regarding long-term efficacy, safety, accessibility and cost-effectiveness. Finally, diabetic neuropathy should increasingly be managed through a

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 8| August 2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753|| ISI Value: 1.188

multidisciplinary and preventive framework. Optimal metabolic management, physical activity, patient education, regular foot assessment, pain management and treatment of associated complications should remain central to care. Future advances will ideally combine these established strategies with therapies capable of protecting nerves and promoting regeneration.

Overall, the future of diabetic neuropathy management lies in moving beyond predominantly symptomatic treatment toward early detection, personalised intervention and genuine disease modification. Continued collaboration between basic scientists, clinicians and pharmaceutical researchers will be essential to convert advances in understanding neuropathic mechanisms into safe, effective and clinically meaningful therapies.

9. CONCLUSION

Diabetic neuropathy is a complex and progressive neurological complication of diabetes mellitus arising from the interaction of metabolic, oxidative, mitochondrial, vascular and inflammatory abnormalities. Although distal symmetric polyneuropathy remains the most common clinical manifestation, the condition encompasses a broad spectrum of sensory, motor and autonomic disturbances that can significantly affect functional capacity and quality of life. Persistent hyperglycaemia, dyslipidaemia, oxidative stress, mitochondrial dysfunction, microvascular impairment and neuroinflammation collectively contribute to neuronal and axonal injury, while impaired neurotrophic support limits effective nerve repair. Current management primarily focuses on optimising glycaemic and metabolic control, reducing neuropathic pain and preventing complications, particularly diabetic foot complications. Pharmacological agents such as gabapentinoids, serotonin–norepinephrine reuptake inhibitors, tricyclic antidepressants and selected sodium-channel–modulating drugs remain important options for symptomatic treatment. However, these approaches do not consistently reverse established nerve damage, highlighting a major unmet therapeutic need. Recent advances have expanded the therapeutic landscape beyond conventional symptom management. Neuromodulation, particularly high-frequency spinal cord stimulation, has demonstrated promising clinical benefits in selected patients with refractory painful diabetic neuropathy. At the same time, regenerative medicine, neurotrophic strategies, mitochondrial protection, anti-inflammatory interventions, metabolic targets and advanced drug-delivery systems are being investigated as potential mechanism-based approaches.

The future management of diabetic neuropathy will likely depend on early identification, personalised treatment and development of genuine disease-modifying therapies capable of protecting or restoring peripheral nerve function. Continued translational research and well-designed clinical trials are essential to determine whether emerging strategies can provide durable neurological recovery. An integrated approach combining established preventive care with emerging therapeutic technologies may ultimately reduce the clinical and socioeconomic burden of diabetic neuropathy.

10. REFERENCES

1. *American Diabetes Association Professional Practice Committee for Diabetes. 12. Retinopathy, neuropathy, and foot care: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S261–S276. doi:10.2337/dc26-S012.*
2. *Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, Bril V, Russell JW, Viswanathan V. Diabetic neuropathy. Nature Reviews Disease Primers. 2019;5(1):42. doi:10.1038/s41572-019-0097-9.*
3. *Sloan G, Selvarajah D, Tesfaye S. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nature Reviews Endocrinology. 2021;17(7):400–420. doi:10.1038/s41574-021-00496-z.*
4. *Iqbal Z, Azmi S, Yadav R, Ferdousi M, Kumar M, Cuthbertson DJ, Lim J, Malik RA, Alam U. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clinical Therapeutics.2018;40(6):828–849. doi:10.1016/j.clinthera.2018.04.001.*
5. *Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154. doi:10.2337/dc16-2042.*
6. *Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–2293. doi:10.2337/dc10-1303.*
7. *Feldman EL, Nave KA, Jensen TS, Bennett DLH. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron.2017;93(6):1296–1313. doi:10.1016/j.neuron.2017.02.005.*
8. *Slangen R, Schaper NC, Faber CG, Joosten EA, Kessels AGH, van Kleef M. Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: a prospective two-center randomized controlled trial. Diabetes Care. 2014;37(11):3016–3024. doi:10.2337/dc14-0684.*
9. *Petersen EA, Stauss TG, Scowcroft JA, Brooks ES, White JL, Sills SM, et al. Effect of high-frequency (10-kHz) spinal cord stimulation in patients with painful diabetic neuropathy: a randomized clinical trial. JAMA Neurology. 2021;78(6):687–698. doi:10.1001/jamaneurol.2021.0538.*
10. *Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28(4):956–962. doi:10.2337/diacare.28.4.956.*
11. *Ziegler D, Papanas N, Vinik AI, Shaw JE. Epidemiology of polyneuropathy in diabetes and prediabetes. Handbook of Clinical Neurology. 2014;126:3–22. doi:10.1016/B978-0-444-53480-4.00001-1.*
12. *Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA, Baconja M, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes/Metabolism Research and Reviews. 2011;27(7):629–638. doi:10.1002/dmrr.1225.*